NO320877B1 - Anvendelse av en immun-potensierende dose av minst ett thymosin eller immunsystempotensierende thymosinfragment - Google Patents
Anvendelse av en immun-potensierende dose av minst ett thymosin eller immunsystempotensierende thymosinfragment Download PDFInfo
- Publication number
- NO320877B1 NO320877B1 NO19953473A NO953473A NO320877B1 NO 320877 B1 NO320877 B1 NO 320877B1 NO 19953473 A NO19953473 A NO 19953473A NO 953473 A NO953473 A NO 953473A NO 320877 B1 NO320877 B1 NO 320877B1
- Authority
- NO
- Norway
- Prior art keywords
- patients
- thymosin
- hepatitis
- treatment
- interferon
- Prior art date
Links
- 102000007501 Thymosin Human genes 0.000 title claims abstract description 45
- 108010046075 Thymosin Proteins 0.000 title claims abstract description 45
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 title claims abstract description 32
- 238000011282 treatment Methods 0.000 claims abstract description 52
- 108010050904 Interferons Proteins 0.000 claims abstract description 37
- 102000014150 Interferons Human genes 0.000 claims abstract description 37
- 229940079322 interferon Drugs 0.000 claims abstract description 30
- 241000124008 Mammalia Species 0.000 claims abstract description 18
- 208000010710 hepatitis C virus infection Diseases 0.000 claims abstract description 11
- 239000012634 fragment Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 210000000987 immune system Anatomy 0.000 claims description 5
- 230000003389 potentiating effect Effects 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 241000711549 Hepacivirus C Species 0.000 abstract description 26
- 208000005176 Hepatitis C Diseases 0.000 abstract description 18
- 238000000034 method Methods 0.000 abstract description 11
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 29
- 108010082126 Alanine transaminase Proteins 0.000 description 29
- 210000002966 serum Anatomy 0.000 description 20
- 230000000694 effects Effects 0.000 description 15
- 230000004044 response Effects 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 208000015181 infectious disease Diseases 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 11
- 208000006454 hepatitis Diseases 0.000 description 10
- 229940047124 interferons Drugs 0.000 description 10
- 231100000283 hepatitis Toxicity 0.000 description 8
- 238000012317 liver biopsy Methods 0.000 description 7
- 239000000902 placebo Substances 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000003442 weekly effect Effects 0.000 description 6
- 108010047761 Interferon-alpha Proteins 0.000 description 5
- 102000006992 Interferon-alpha Human genes 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 210000001541 thymus gland Anatomy 0.000 description 5
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- 206010008909 Chronic Hepatitis Diseases 0.000 description 4
- 206010019799 Hepatitis viral Diseases 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 201000001862 viral hepatitis Diseases 0.000 description 4
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 3
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 3
- 208000006154 Chronic hepatitis C Diseases 0.000 description 3
- 206010019755 Hepatitis chronic active Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- -1 TF-5 Chemical compound 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000009266 disease activity Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 2
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229940044627 gamma-interferon Drugs 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 230000008935 histological improvement Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 206010065051 Acute hepatitis C Diseases 0.000 description 1
- UCTWMZQNUQWSLP-UHFFFAOYSA-N Adrenaline Natural products CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 208000018565 Hemochromatosis Diseases 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 206010019791 Hepatitis post transfusion Diseases 0.000 description 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
- 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 description 1
- 108010078049 Interferon alpha-2 Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010048043 Macrophage Migration-Inhibitory Factors Proteins 0.000 description 1
- 102100037791 Macrophage migration inhibitory factor Human genes 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000283923 Marmota monax Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000018839 Wilson disease Diseases 0.000 description 1
- 241001492404 Woodchuck hepatitis virus Species 0.000 description 1
- 208000037621 acute hepatitis C virus infection Diseases 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 229940102884 adrenalin Drugs 0.000 description 1
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000947 anti-immunosuppressive effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940065638 intron a Drugs 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/027,500 US6001799A (en) | 1991-09-13 | 1993-03-05 | Method of treating hepatitis C in non-responders to interferon treatment |
| PCT/US1994/002320 WO1994020131A1 (en) | 1993-03-05 | 1994-03-03 | Method of treating hepatitis c in non-responders to interferon treatment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO953473D0 NO953473D0 (no) | 1995-09-04 |
| NO953473L NO953473L (no) | 1995-09-04 |
| NO320877B1 true NO320877B1 (no) | 2006-02-06 |
Family
ID=21838079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19953473A NO320877B1 (no) | 1993-03-05 | 1995-09-04 | Anvendelse av en immun-potensierende dose av minst ett thymosin eller immunsystempotensierende thymosinfragment |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP0687181B1 (pt) |
| JP (1) | JPH06279309A (pt) |
| KR (1) | KR100306024B1 (pt) |
| CN (1) | CN1072961C (pt) |
| AT (1) | ATE204760T1 (pt) |
| AU (1) | AU683248B2 (pt) |
| CA (1) | CA2157479C (pt) |
| DE (1) | DE69428112T2 (pt) |
| DK (1) | DK0687181T3 (pt) |
| ES (1) | ES2162862T3 (pt) |
| FI (1) | FI954127A (pt) |
| GR (1) | GR3037021T3 (pt) |
| MY (1) | MY121198A (pt) |
| NO (1) | NO320877B1 (pt) |
| PT (1) | PT687181E (pt) |
| SG (1) | SG64894A1 (pt) |
| WO (1) | WO1994020131A1 (pt) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997016204A1 (en) | 1995-11-02 | 1997-05-09 | Schering Corporation | Continuous low-dose cytokine infusion therapy |
| US7208167B2 (en) | 2000-08-07 | 2007-04-24 | Sciclone Pharmaceuticals, Inc. | Treatment of hepatitis C with thymosin and peptide combination therapy |
| EP1311286B1 (en) * | 2000-08-07 | 2006-07-12 | Sciclone Pharmaceuticals, Inc. | Treatment of hepatitis c with thymosin and pegylated interferon |
| EA008037B1 (ru) | 2003-03-28 | 2007-02-27 | Сциклон Фармасьютикалс, Инк. | ЛЕЧЕНИЕ ИНФЕКЦИЙ, ВЫЗЫВАЕМЫХ ГРИБАМИ p. ASPERGILLUS, С ПОМОЩЬЮ ТИМОЗИНА АЛЬФА 1 |
| CA2649063C (en) * | 2006-05-02 | 2014-11-25 | Luigina Romani | Use of thymosin .alpha.1, alone or in combination with ptx3 or ganciclovir, for the treatment of cytomegalovirus infection |
| US9034837B2 (en) * | 2009-04-24 | 2015-05-19 | Roche Innovation Center Copenhagen A/S | Pharmaceutical compositions for treatment of HCV patients that are poor-responders to interferon |
| ES2537785T3 (es) | 2009-05-08 | 2015-06-12 | Sciclone Pharmaceuticals, Inc. | Péptidos de alfa timosina como potenciadores de vacunas |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1216056B (it) * | 1988-03-11 | 1990-02-22 | Sclavo Spa | Composizioni farmaceutiche contenenti timosina alfa 1. |
| TW224053B (pt) * | 1991-09-13 | 1994-05-21 | Paul B Chretien |
-
1993
- 1993-09-27 CN CN93119345A patent/CN1072961C/zh not_active Expired - Lifetime
- 1993-12-27 JP JP5331601A patent/JPH06279309A/ja active Pending
-
1994
- 1994-02-18 MY MYPI94000381A patent/MY121198A/en unknown
- 1994-03-03 ES ES94910226T patent/ES2162862T3/es not_active Expired - Lifetime
- 1994-03-03 WO PCT/US1994/002320 patent/WO1994020131A1/en active IP Right Grant
- 1994-03-03 AU AU62759/94A patent/AU683248B2/en not_active Ceased
- 1994-03-03 DK DK94910226T patent/DK0687181T3/da active
- 1994-03-03 EP EP94910226A patent/EP0687181B1/en not_active Expired - Lifetime
- 1994-03-03 PT PT94910226T patent/PT687181E/pt unknown
- 1994-03-03 KR KR1019950703297A patent/KR100306024B1/ko not_active IP Right Cessation
- 1994-03-03 CA CA002157479A patent/CA2157479C/en not_active Expired - Fee Related
- 1994-03-03 AT AT94910226T patent/ATE204760T1/de active
- 1994-03-03 DE DE69428112T patent/DE69428112T2/de not_active Expired - Lifetime
- 1994-03-03 SG SG1996005604A patent/SG64894A1/en unknown
-
1995
- 1995-09-04 FI FI954127A patent/FI954127A/fi unknown
- 1995-09-04 NO NO19953473A patent/NO320877B1/no not_active IP Right Cessation
-
2001
- 2001-10-25 GR GR20010401892T patent/GR3037021T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2157479C (en) | 2000-08-08 |
| NO953473D0 (no) | 1995-09-04 |
| CN1072961C (zh) | 2001-10-17 |
| DE69428112D1 (de) | 2001-10-04 |
| SG64894A1 (en) | 1999-05-25 |
| FI954127A0 (fi) | 1995-09-04 |
| KR100306024B1 (ko) | 2001-11-30 |
| CN1092322A (zh) | 1994-09-21 |
| KR960700741A (ko) | 1996-02-24 |
| FI954127A (fi) | 1995-09-04 |
| ATE204760T1 (de) | 2001-09-15 |
| JPH06279309A (ja) | 1994-10-04 |
| CA2157479A1 (en) | 1994-09-15 |
| MY121198A (en) | 2006-01-28 |
| DE69428112T2 (de) | 2002-03-21 |
| AU6275994A (en) | 1994-09-26 |
| DK0687181T3 (da) | 2001-10-01 |
| AU683248B2 (en) | 1997-11-06 |
| PT687181E (pt) | 2002-01-30 |
| ES2162862T3 (es) | 2002-01-16 |
| NO953473L (no) | 1995-09-04 |
| EP0687181B1 (en) | 2001-08-29 |
| EP0687181A1 (en) | 1995-12-20 |
| GR3037021T3 (en) | 2002-01-31 |
| WO1994020131A1 (en) | 1994-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0603305B1 (en) | Use of a thymosin in the treatment of hepatitis c | |
| Lok et al. | Interferon antibodies may negate the antiviral effects of recombinant α-interferon treatment in patients with chronic hepatitis B virus infection | |
| KR100309059B1 (ko) | 인터페론을함유하는치료학적배합물 | |
| RU2389501C2 (ru) | Применение модифицированных циклоспоринов для лечения заболеваний, вызванных hcv | |
| Grüngreiff et al. | Serum concentrations of sIL-2R, IL-6, TGF-β1, neopterin, and zinc in chronic hepatitis C patients treated with interferon-alpha | |
| Bonkovsky | Therapy of hepatitis C: other options | |
| MX2007000503A (es) | Uso de una combinacion de ciclosporina e interferon pegilado para el tratamiento de hepatitis c(hcv). | |
| Farrell | Therapy of hepatitis C: interferon alfa-n1 trials | |
| NO320877B1 (no) | Anvendelse av en immun-potensierende dose av minst ett thymosin eller immunsystempotensierende thymosinfragment | |
| WO1994001125A1 (en) | Composition and method of treating hepatitis b | |
| Podzamczer et al. | Low‐dose interferon alpha combined with zidovudine in patients with AIDS‐associated Kaposi's sarcoma | |
| WO1994001125A9 (en) | Composition and method of treating hepatitis b | |
| Farhat et al. | Evaluation of efficacy and safety of thymus humoral factor-gamma 2 in the management of chronic hepatitis B | |
| Weiland et al. | Interfered Alpha-2b Treatment of Chronic Posttransfusion Non-A, Non-B Hepatitis: Interim Results of a Randomized Controlled Open Study | |
| JPH07258109A (ja) | Ｃ型肝炎の処置法および処置用組成物 | |
| Mauser‐Bunschoten et al. | Effect and side‐effects of alpha interferon treatment in haemophilia patients with chronic hepatitis C | |
| Yabrov | It is hazardous to treat HIV patients with interferon-α | |
| AU751199B2 (en) | Composition and method of treating hepatitis B | |
| WO2013138064A1 (en) | Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |